par John R. Fischer
, Senior Reporter | January 27, 2021
Strong growth in its diagnostic imaging equipment helped earned Philips’ over $7.2 billion (€6 billion) in Q4 2020, with 7% comparable sales growth.
The company saw high single-digit growth in sales for its diagnostic imaging systems and amassed $2.98 billion (€2.458 billion) in sales in its Diagnosis & Treatment division altogether. It was hindered by a sales decline in its Personal Health section, as well as a mid-single-digit decrease in that of its image-guided therapy and ultrasound systems.
“As a result of our stronger performance in the second half of the year, following a challenging first half due to the impact of COVID-19, our performance was resilient. For the full year 2020 we delivered 3% comparable sales growth, an adjusted EBITA margin of 13.2% and a strong free cash flow of EUR 1.9 billion. Moreover, driven by 9% comparable order intake growth, we continued to gain market share in our healthcare businesses, and ended the year with a strong order book,” said Frans van Houten, CEO of Royal Philips, in a statement.
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs
Income from continuing operations for Q4 increased to more than $7.3 billion (€608 million), while the company’s adjusted EBITA margin improved to 19% during this period. Operating cash flow increased to $1.5 million (€1.3 million).
Philips’ Diagnosis & Treatment division initially saw a 5% nominal decrease from the $3.13 billion (€2.5 billion) it earned the same time last year in sales, though this was up 1% after adjusting for currency changes. The earnings for the division before interest, taxes, and amortization were $381 million (314 million). Declines in image-guided therapy and ultrasound systems were chalked up to the postponement of system sales by COVID-19, and led to a 14% drop in EBITA margin.
Its Personal Health business earned $2.21 billion (€1.8 billion) in sales, down 1% nominally. This, however, was up 5% after adjusting for currency. Sales of oral healthcare products declined in the low single digits. Adjusted EBITA was 20%, and for the full year, the Personal Health businesses saw a 4% decrease in comparable sales and an Adjusted EBITA margin of 13%. The Connected Care business, meanwhile, had a 24% increase in comparable quarterly sales, with double-digit growth in Monitoring & Analytics and Sleep & Respiratory Care. Comparable order intake grew 17%, with strong growth across all businesses, while adjusted EBITA margin increased to 27.2%.
Higher sales in China and Central and Eastern Europe drove sales for Philips, though this was partially offset by the Middle East and Turkey. It was hindered by low-single-digit growth in Western Europe and a mid-single-digit decrease in North America. The company also finished off the year with 25 new long-term strategic partnerships in Q4, including a five-year technology and innovation partnership with Rennes University Hospital in France. Back to HCB News